Pay in 4 interest-free payments of $6.71 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Unlike traditional phosphodiesterase-5 inhibitors that target vascular function, PT-141 acts centrally through brain melanocortin pathways, making it the first centrally-acting agent approved for sexual dysfunction
Josh Shipman received his PhD in chemistry from the University of Kansas, he joined the FDA as an ORISE post-doctoral fellow in 2019 and converted to a full-time chemist position in 2021
[12:25] A Like, I don't know
80,81 Additionally, it is theorized that combining PDE inhibitors with GLP-1 RAs may provide additive benefits in metabolic and cardiovascular contexts in aging models, although supporting human data remain limited
US$ 26.45
US$ 28.30
US$ 23.35
US$ 25.80
US$ 20.71
US$ 22.74
US$ 28.40
